Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +63

Here's What to Expect From Cigna Group's Next Earnings Report

🏢 The Cigna Group (CI), headquartered in Bloomfield, Connecticut, operates as a major provider of insurance and pharmacy benefit management services.

📅 Wall Street expects CI to release its fiscal first-quarter 2026 earnings results before the market opens on Thursday, April 30.

💰 Analysts forecast quarterly EPS of $7.57, representing a 12.3% year-over-year increase from $6.74 in the same period last year.

📊 CI has beaten Wall Street bottom-line estimates for the last four consecutive quarters, including recent Q4 earnings that surpassed consensus by $0.20 per share.

🔮 For the fiscal year ending December 2025, analysts project a profit of $30.32 per share, a slight increase from $29.84 in fiscal 2025.

📈 Long-term growth expectations remain strong, with estimated EPS reaching $33.32 in fiscal 2027 for a 9.9% year-over-year gain.

📉 Despite positive earnings forecasts, CI stock has fallen 13% over the past 52 weeks, significantly underperforming both the S&P 500 and health care sector ETFs.

🎉 Shares recently rallied 4.7% on February 5 following Q4 results that saw revenue jump 10.4% to $72.5 billion and adjusted EPS rise 21.7%.

🚀 Management cited robust expansion in EverNorth specialty services, biosimilar adoption, and operational discipline as key drivers of recent performance.

🏆 Investor sentiment is highly bullish, with 18 out of 23 analysts rating CI as "Strong Buy" and two rating it as "Moderate Buy."

💵 The average Wall Street price target for CI stands at $338.32, suggesting roughly 21.5% potential upside from current trading levels.

Bullish Signals
  • Analysts expect Cigna Group (CI) to report a profit of $7.57 per share in fiscal Q1 2026, representing a 12.3% increase from the year-ago quarter of $6.74.
  • The company has topped Wall Street's bottom-line estimates in each of the last four quarters, with previous earnings of $8.08 per share exceeding forecasts by 2.7%.
  • For the current fiscal year ending in December, analysts project CI to report a profit of $30.32 per share, reflecting a 1.6% increase from $29.84 in fiscal 2025.
  • EPS is forecasted to grow an additional 9.9% year-over-year to reach $33.32 in fiscal 2027.
  • Shares of CI surged 4.7% on Feb. 5 following better-than-expected Q4 results, where revenue jumped 10.4% year over year to $72.5 billion against consensus expectations of $69.9 billion.
  • Adjusted EPS advanced 21.7% from the year-ago quarter to $8.08 in Q4, surpassing the Wall Street estimate of $7.88.
  • Robust expansion in EverNorth specialty and care services, successful biosimilar adoption, and operational discipline across health benefits business supported recent results.
  • Wall Street analysts hold a 'Strong Buy' rating overall with 18 out of 23 analysts recommending 'Strong Buy', two indicating 'Moderate Buy', and three suggesting 'Hold'.
  • The mean price target for CI is $338.32, indicating 21.5% potential upside from current trading levels.
Risk Factors
  • Cigna Group (CI) has declined 13% over the past 52 weeks, considerably underperforming both the S&P 500 Index's ($SPX) 25.1% return and the State Street Health Care Select Sector SPDR ETF's (XLV) 7.6% uptick over the same time frame.
  • Three out of 23 analysts covering CI suggest a 'Hold' rating, with three recommending 'Moderate Buy', indicating potential skepticism from some Wall Street firms despite the overall positive sentiment.
Full Analysis
The Cigna Group (CI), headquartered in Bloomfield, Connecticut with a market capitalization of $73.4 billion, is preparing to release its fiscal first-quarter earnings for 2026 on Thursday, April 30, before the market opens. Analysts project the company will report an earnings per share (EPS) of $7.57, which represents a 12.3% increase from the $6.74 recorded in the same quarter last year. This expectation follows a streak of four consecutive quarters where the company has exceeded Wall Street's bottom-line estimates, including a recent fourth-quarter result that beat forecasts by 2.7% with earnings of $8.08 per share. For the fiscal year ending in December, consensus estimates suggest CI will post a profit of $30.32 per share, marking a 1.6% increase from the $29.84 reported in fiscal 2025. Looking further ahead, EPS is forecast to grow by 9.9% year-over-year to reach $33.32 in fiscal 2027. Despite this optimism, CI stock has underperformed significantly over the past 52 weeks, declining 13% compared to the S&P 500 Index's 25.1% gain and the State Street Health Care Select Sector SPDR ETF’s 7.6% rise during the same period. Recent positive performance is highlighted by a 4.7% surge on February 5, driven by better-than-expected Q4 results where revenue jumped 10.4% to $72.5 billion, surpassing consensus expectations of $69.9 billion. Adjusted earnings per share for that quarter advanced 21.7% to $8.08, supported by expansion in EverNorth specialty services, biosimilar adoption, and operational discipline. Wall Street sentiment remains favorable, with an aggregate "Strong Buy" rating from the 18 analysts recommending strong or moderate buy among 23 covering the stock, while three suggest a "Hold." The mean price target stands at $338.32, indicating a potential upside of 21.5% from current levels.